natgillin/translations-raw huggingface dataset:
Hyperbilirubinaemia occurred more frequently at doses exceeding 2.4 g/day compared to doses less than 2.4 g/day.
Hiperbilirubinemija se češće javljala pri dozama višima od 2,4 g na dan u odnosu na doze niže od 2,4 g na dan.
Analysis of plasma and urine samples from subjects who received indinavir indicated that indinavir metabolites had little proteinase inhibitory activity.
Analiza uzoraka plazme i mokraće ispitanika koji su primili indinavir pokazala je da metaboliti indinavira imaju slab inhibitorni učinak na proteinazu.
There are also other side effects that you may get while taking this medicine such as increased bleeding in haemophiliacs, muscle problems, signs of infection, and bone problems.
Postoje i druge nuspojave koje se mogu javiti kod uzimanja ovog lijeka, poput pojačanog krvarenja u bolesnika s hemofilijom, tegoba s mišićima, znakova infekcije i tegoba s kostima.
Dose modification of calcium channel blockers should be considered when coadministered with indinavir/ritonavir as it may result in an increased response.
Treba razmotriti prilagodbu doze blokatora kalcijevih kanala kad se primjenjuju istodobno s indinavirom/ritonavirom jer može doći do pojačanog odgovora.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.
CRIXIVAN je u kombinaciji s antiretrovirusnim nukleozidnim analozima indiciran za liječenje odraslih bolesnika zaraženih virusom HIV-1.
Therefore, other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of indinavir.
Stoga, druge tvari koje dijele isti metabolički put ili mijenjaju aktivnost CYP3A4 mogu utjecati na farmakokinetiku indinavira.
If you take more CRIXIVAN than you should
Ako uzmete više lijeka CRIXIVAN nego što ste trebali
Do not take either CRIXIVAN or ritonavir if any of the above applies to you.
Nemojte uzimati ni CRIXIVAN niti ritonavir ako se nešto od gore navedenog odnosi na Vas.
The observed amino acid substitutions appeared to accumulate sequentially and in no consistent order, probably as a result of ongoing viral replication.
Čini se da se opažene aminokiselinske supstitucije akumuliraju jedna za drugom bez ustaljenog redoslijeda, najvjerojatnije kao posljedica neprekidne replikacije virusa.
The design of the study does not allow for definitive evaluation of the effect of saquinavir on indinavir, but suggests there is less than a two-fold increase in indinavir AUC8h during co-administration with saquinavir
Dizajn ispitivanja ne omogućuje konačnu ocjenu učinka sakvinavira na indinavir, ali pokazuje da kod istodobne primjene sa sakvinavirom dolazi do manje od dvostrukog povećanja AUC8h indinavira.
This could be dry toast with jam or cornflakes with skimmed or low-fat milk and sugar.
To može biti prepečenac s marmeladom ili kukuruzne pahuljice s obranim ili nemasnim mlijekom i šećerom.
These adverse reactions were: nausea (35.3 %), headache (25.2 %), diarrhoea (24.6 %), asthenia/fatigue (24.3 %), rash (19.1 %), taste perversion (19.1 %), dry skin (16.2 %), abdominal pain (14.6 %), vomiting (11.0 %), dizziness (10.7 %).
Te su nuspojave bile mučnina (35,3%), glavobolja (25,2%), proljev (24,6%), astenija/umor (24,3%), osip (19,1%), promjena osjeta okusa (19,1%), suha koža (16,2%), bol u abdomenu (14,6%), povraćanje (11,0%), omaglica (10,7%).
Nephrolithiasis has occurred with indinavir therapy in adult patients with a cumulative frequency of 12.4 % (range across individual trials: 4.7 % to 34.4 %).
Tijekom liječenja indinavirom nefrolitijaza se u odraslih bolesnika javljala s ukupnom učestalošću od 12,4% (raspon između pojedinačnih ispitivanja: 4,7% do 34,4%).
Administration with light meals (e.g., dry toast with jam or fruit conserve, apple juice, and coffee with skimmed or fat-free milk and sugar or corn flakes, skimmed or fat-free milk and sugar) resulted in plasma concentrations comparable to the corresponding fasted values.
Primjena uz lagane obroke (npr. prepečenac s marmeladom ili džemom od voća, jabučni sok i kava s obranim ili nemasnim mlijekom i šećerom ili kukuruzne pahuljice s obranim ili nemasnim mlijekom i šećerom) dovela je do koncentracija u plazmi koje su bile slične vrijednostima natašte.
Eighteen patients completed the study to week 48.
Osamnaest je bolesnika dovršilo 48 tjedana ispitivanja.
• This is because reducing or missing doses will make it more likely that HIV will become resistant to CRIXIVAN.
• Naime, smanjenje ili propuštanje doze povećava vjerojatnost da će HIV razviti otpornost na
It is not known whether indinavir is dialyzable by peritoneal or haemodialysis.
Nije poznato može li se indinavir ukloniti peritonealnom dijalizom ili hemodijalizom.
In controlled clinical trials conducted world-wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15 % females).
U kontroliranim kliničkim ispitivanjima provedenima diljem svijeta indinavir je primjenjivan samostalno ili u kombinaciji s drugim antiretrovirusnim lijekovima (zidovudin, didanozin, stavudin i/ili lamivudin) u približno 2000 bolesnika, od kojih su većina bili odrasli muškarci bijele rase (15% žena).
Loss of suppression of viral RNA levels occurred in some patients; however, CD4 cell counts were often sustained above pre-treatment levels.
U nekih je bolesnika došlo do gubitka supresije virusne RNK, međutim, broj CD4 stanica se često održao na višoj razini nego prije liječenja.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Iako se smatra da ima više uzroka (uključujući uzimanje kortikosteroida, konzumiranje alkohola, tešku imunosupresiju, povećan indeks tjelesne mase), osteonekroza je prijavljena posebno u bolesnika s uznapredovalom HIV bolešću i/ili u bolesnika na dugotrajnoj kombiniranoj antiretrovirusnoj terapiji.
Rifampicin is a strong CYP3A4 inducer and has been shown to cause a 92 % decrease in indinavir AUC which can result in virological failure and resistance development.
Rifampicin je snažan induktor CYP3A4 koji može sniziti AUC indinavira za 92% te tako dovesti do virološkog neuspjeha i razvoja rezistencije.
Given that substantially lower antepartum exposures have been observed in a small study of HIV-infected pregnant patients and the limited data in this patient population, indinavir use is not recommended in HIV-infected pregnant patients (see section 5.2).
Budući da je u jednom manjem ispitivanju u kojem su sudjelovale trudnice zaražene HIV-om primijećena značajno niža izloženost lijeku prije poroda i s obzirom na malobrojne podatke dostupne za ovu populaciju bolesnica, primjena indinavira ne preporučuje se u trudnica zaraženih HIV-om (vidjeti dio 5.2).
When indinavir is administered as monotherapy resistant viruses rapidly emerge (see section 5.1).
Kada se indinavir primjenjuje kao monoterapija, brzo se razvijaju rezistentni virusi (vidjeti dio 5.1).
The maximum non-lethal oral dose of indinavir was at least 5,000 mg/kg in rats and mice, the highest dose tested in acute toxicity studies.
Maksimalna nesmrtonosna peroralna doza indinavira u štakora i miševa iznosila je najmanje 5000 mg/kg, što je najviša doza ispitivana u istraživanjima akutne toksičnosti.
Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle.
Indinavir se reverzibilno veže za aktivno mjesto proteaze i kompetitivno inhibira taj enzim čime sprječava cijepanje virusnih poliproteinskih prekursora do kojeg dolazi tijekom sazrijevanja novonastale virusne čestice.
• warfarin - used to thin the blood
• varfarin - koristi se za razrjeđivanje krvi
• amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - used for high blood pressure and some heart problems.
• amlodipin, felodipin, nifedipin, nikardipin, digoksin, diltiazem - koriste se za liječenje visokog krvnog tlaka i nekih srčanih tegoba
No significant difference in exposure was seen when the regimen was given with a high-fat meal.
Nije primijećena značajna razlika u izloženosti kada je doza primijenjena uz punomastan obrok.
If you stop taking CRIXIVAN
Ako prestanete uzimati CRIXIVAN
Desiccant should not be removed from the container.
Sredstvo za sušenje se ne smije uklanjati iz spremnika.
For information regarding diet or the effect of food on indinavir absorption (see sections 4.2 and 5.2).
Za informacije o prehrani i utjecaju hrane na apsorpciju indinavira vidjeti dijelove 4.2 i 5.2.
Do not take CRIXIVAN if any of the above applies to you.
Nemojte uzimati CRIXIVAN ako se nešto od navedenog odnosi na Vas.
• fexofenadine, loratidine - antihistamines used for hay fever and other allergic conditions
• feksofenadin, loratadin - antihistaminici koji se koriste za peludnu groznicu i druga alergijska stanja
Antiretroviral activity was unaltered when didanosine was administered 3 hours after treatment with indinavir.
Nije došlo do promjene u antiretrovirusnom djelovanju kada se didanozin primijenio 3 sata nakon indinavira.
The cumulative frequency of nephrolithiasis events increases with increasing exposure to CRIXIVAN; however, the risk over time remains relatively constant.
Ukupna učestalost slučajeva nefrolitijaze povećava se s povećanjem izloženosti lijeku CRIXIVAN, međutim, rizik tijekom vremena ostaje relativno nepromijenjen.
The pharmacokinetics of indinavir taken as indinavir sulphate salt (from opened hard capsules) mixed in apple sauce were generally comparable to the pharmacokinetics of indinavir taken as hard capsules, under fasting conditions.
Farmakokinetika indinavira primijenjenog u obliku soli indinavirsulfata (iz otvorenih tvrdih kapsula) pomiješan s jabučnim sokom u načelu je bila slična farmakokinetici indinavira primijenjenog u obliku tvrdih kapsula natašte.
180 hard capsules 270 hard capsules 360 hard capsules
180 tvrdih kapsula 270 tvrdih kapsula 360 tvrdih kapsula
No dose recommendations for indinavir/ritonavir with rifabutin could be given, therefore the combination is not recommended.
Ne može se dati preporuka za doziranje indinavira/ritonavira s rifabutinom, pa se ta kombinacija ne preporučuje.
Morphine
Morfij
If you are not sure, talk to your doctor, pharmacist or nurse before taking CRIXIVAN.
Ako niste sigurni, obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete CRIXIVAN.
• An example of another medicine that might be given to you, at the same time as CRIXIVAN,
• Primjer drugog lijeka koji biste mogli dobivati istodobno s lijekom CRIXIVAN je ritonavir.
Excipient with known effect Each 400 mg capsule contains 149.6 mg of lactose.
Pomoćna tvar s poznatim učinkom Jedna kapsula od 400 mg sadrži 149,6 mg laktoze.
Indinavir is rapidly absorbed in the fasted state with a time to peak plasma concentration of 0.8 hours ± 0.3 hours (mean ± S.D.).
Indinavir se natašte brzo apsorbira pa vrijeme postizanja vršne koncentracije u plazmi iznosi 0,8 sati ± 0,3 sata (srednja vrijednost ± SD).
Such problems might be due to a bone disease called ‘osteonecrosis' (loss of blood supply to the bone causing bone death), which can occur months to years after starting HIV therapy.
Ove tegobe mogu biti povezane s bolešću kostiju koja se zove ‘osteonekroza'(dolazi do propadanja kostiju zbog prestanka opskrbe kosti krvlju), a može se pojaviti više mjeseci ili godina nakon početka liječenja HIV infekcije.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolesnike treba uputiti da potraže liječničku pomoć ako osjete bol u zglobovima, ukočenost zglobova ili imaju poteškoća pri kretanju.
For sildenafil and tadalafil, same recommendations as for indinavir without ritonavir boosting (see Table 1).
Za sildenafil i tadalafil vrijede iste preporuke kao i za indinavir koji nije pojačan ritonavirom (vidjeti Tablicu 1).
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Ovakve su se reakcije u pravilu javljale u prvih nekoliko tjedana ili mjeseci nakon uvođenja kombiniranog antiretrovirusnog liječenja.
Limited data are available on the pharmacokinetics of indinavir in association with low dose ritonavir.
Dostupni su malobrojni podaci o farmakokinetici indinavira primijenjenog u kombinaciji s niskom dozom ritonavira.
Combination contraindicated due to an increased risk of myopathy including rhabdomyolysis.
Kombinacija je kontraindicirana zbog povećanog rizika od miopatije, uključujući rabdomiolizu.
Indinavir AUC:  28 % Nevirapine:  (CYP3A induction)
AUC indinavira:  28% nevirapin:  (indukcija CYP3A)
Because it is unknown whether indinavir will exacerbate physiologic hyperbilirubinaemia in neonates, careful consideration must be given to the use of indinavir in pregnant women at the time of delivery (see section 4.8).
Budući da nije poznato izaziva li indinavir egzacerbaciju fiziološke hiperbilirubinemije u novorođenčadi, nužno je dobro razmisliti o primjeni indinavira u trudnica u vrijeme poroda (vidjeti dio 4.8).
Other Anti-infectives Atovaquone
Ostali antiinfektivi Atovakvon
• quetiapine - used for some mental illnesses such as schizophrenia, bipolar disorder and major depressive disorder
• kvetiapin - koristi se za liječenje psihičkih bolesti poput shizofrenije, bipolarnog poremećaja te velikog depresivnog poremećaja.
Amprenavir AUC: ↑ 90 % Indinavir: ↔
AUC amprenavira: ↑ 90% indinavir: ↔
The interaction of indinavir or indinavir/ritonavir with pravastatin or fluvastatin is not known (see section 4.5).
Interakcija indinavira ili indinavira/ritonavira s pravastatinom ili fluvastatinom nije poznata (vidjeti dio 4.5).
• venlafaxine, trazodone - used for depression
• venlafaksin, trazodon - koriste se za depresiju
• If you are also taking ritonavir, then you can take CRIXIVAN at any time of the day with or without food.
• Ako uzimate i ritonavir, CRIXIVAN možete uzeti u bilo koje doba dana, s hranom ili bez nje.
The combination of trazodone with indinavir/ritonavir should be used with caution, initiating trazodone at the lowest dose and monitoring for clinical response and tolerability.
Kombinaciju trazodona i indinavira/ritonavira treba primjenjivati uz oprez, započinjući liječenje trazadonom u najnižoj dozi te prateći klinički odgovor i podnošljivost.
Another published study evaluated the efficacy and safety of indinavir/ritonavir 400/100 mg every 12 hours in 40 antiretroviral-naïve patients.
Jedno drugo objavljeno ispitivanje ocijenilo je djelotvornost i sigurnost indinavira/ritonavira u dozi od 400/100 mg svakih 12 sati u 40 bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima.
Nephrolithiasis and tubulointerstitial nephritis
Nefrolitijaza i tubulointersticijski nefritis
• Do not take CRIXIVAN with food that is high in calories, fat and protein.
• ne uzimate CRIXIVAN s hranom koja je bogata kalorijama, mastima i proteinima.
• liver problems - people with ‘chronic hepatitis B or C' or ‘cirrhosis' who are treated with ‘antiretroviral' medicines are more likely to have serious and potentially fatal liver side effects with this medicine.
• tegobe s jetrom - osobe s ‘kroničnim hepatitisom B ili C' ili ‘cirozom' koje se liječe ‘antiretrovirusnim' lijekovima sklonije su razvoju ozbiljnih i potencijalno smrtonosnih jetrenih nuspojava kod primjene ovog lijeka.
Indinavir AUC:  11 % Sildenafil AUC  340 %
AUC indinavira:  11% AUC sildenafila  340%
When loss of viral RNA suppression occurred, it was typically associated with replacement of circulating susceptible virus with resistant viral variants.
Gubitak supresije virusne RNK u načelu se povezivao sa zamjenom osjetljivoga cirkulirajućeg virusa s rezistentnim virusnim varijantama.
Isolated asymptomatic hyperbilirubinaemia (total bilirubin  2.5 mg/dL, 43 mcmol/L) was reported predominantly as elevated indirect bilirubin and rarely associated with elevations in ALT, AST, or alkaline phosphatase, has occurred in approximately 14 % of patients treated with CRIXIVAN alone or in combination with other antiretroviral agents.
Izolirana asimptomatska hiperbilirubinemija (ukupan bilirubin ≥ 2,5 mg/dl, 43 µmol/l), koja je prijavljivana prvenstveno u obliku povišene razine indirektnog bilirubina i rijetko bila udružena s povišenim vrijednostima ALT-a, AST-a ili alkalne fosfataze, nastupila je u otprilike 14% bolesnika liječenih lijekom CRIXIVAN samim ili u kombinaciji s drugim antiretrovirusnim lijekovima.
Indinavir must not be given with ritonavir to patients with decompensated liver disease as ritonavir is principally metabolized and eliminated by the liver (see section 4.4).
Indinavir se ne smije primjenjivati s ritonavirom u bolesnika s dekompenziranom bolešću jetre jer se ritonavir metabolizira i eliminira prvenstveno putem jetre (vidjeti dio 4.4).
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Bolesnici s već postojećom disfunkcijom jetre, uključujući kronični aktivni hepatitis, imaju tijekom kombiniranog antiretrovirusnog liječenja učestalije poremećaje jetrene funkcije te ih stoga treba nadzirati u skladu s uobičajenom praksom.
This overall safety profile remained similar for 107 patients treated with CRIXIVAN monotherapy or in combination with NRTI(s) for up to 48 weeks.
Ukupan sigurnosni profil ostao je sličan u 107 bolesnika liječenih lijekom CRIXIVAN u monoterapiji ili u kombinaciji s jednim ili više NRTI-ja tijekom najviše 48 tjedana.
As a result of the short half-life, 1.8 ± 0.4 hours, only a minimal increase in plasma concentrations occurred after multiple dosing.
Zbog kratkog poluvijeka od 1,8 ± 0,4 sati nakon primjene višekratnih doza primijećen je samo minimalan porast koncentracije u plazmi.
The use of rifampicin with indinavir is contraindicated.
Primjena rifampicina s indinavirom je kontraindicirana.
In dogs, a slight increase in resorptions was seen; however, all foetuses in medication-treated animals were viable, and the incidence of live foetuses in medication-treated animals was comparable to that in controls.
U pasa je uočeno blago povećanje resorpcije; međutim, svi fetusi u životinja koje su primale lijek bili su vijabilni, a incidencija živih fetusa u životinja koje su primale lijek bila je slična onoj u kontrolnoj skupini.
Ritonavir AUC ↓ 36 % Ritonavir Cmin: 39 %
AUC ritonavira ↓ 36% Cmin ritonavira: 39%
• dry mouth
• utrnulost usta
What CRIXIVAN contains
Što CRIXIVAN sadrži
• ‘haemophilia' - CRIXIVAN may make you more likely to bleed.
• ‘hemofiliju' - CRIXIVAN može povećati sklonost krvarenju.
No specific interaction studies have been performed with the boosted dose 400 mg indinavir with 100 mg ritonavir.
Nisu provedena posebna ispitivanja interakcija s dozom indinavira od 400 mg pojačanom sa 100 mg ritonavira.
Excipient with known effect Each 200 mg capsule contains 74.8 mg lactose.
Pomoćna tvar s poznatim učinkom Jedna kapsula od 200 mg sadrži 74,8 mg laktoze.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Prijavljeni su i autoimuni poremećaji (kao što je Gravesova bolest i autoimuni hepatitis); međutim, prijavljeno vrijeme do pojave je različito i ti se događaji mogu javiti više mjeseci nakon uvođenja liječenja (vidjeti dio 4.4).
Coadministration of ritonavir and ketoconazole caused an increased incidence of gastrointestinal and hepatic adverse events.
Istodobna primjena ritonavira i ketokonazola dovela je do povećane incidencije gastrointestinalnih i jetrenih nuspojava.
nausea, vomiting, diarrhoea, dyspepsia flatulence, dry mouth, acid regurgitation hepatitis, including reports of hepatic failure, pancreatitis.
mučnina, povraćanje, proljev, dispepsija flatulencija, suha usta, regurgitacija želučane kiseline hepatitis, uključujući prijave zatajenja jetre, pankreatitis
Concomitant use of medicinal products that are inducers of CYP3A4, such as carbamazepine, phenobarbital and phenytoin may reduce indinavir plasma concentrations.
Istodobna primjena lijekova koji induciraju CYP3A4, poput karbamazepina, fenobarbitala i fenitoina, može sniziti koncentracije indinavira u plazmi.
CRIXIVAN should be administered by physicians who are experienced in the treatment of HIV infection.
CRIXIVAN mora primijeniti liječnik s iskustvom u liječenju HIV infekcije.
Acute haemolytic anaemia
Akutna hemolitička anemija
• fluconazole - used for fungal infections
• flukonazol - koristi se za gljivične infekcije
Zidovudine AUC: ↑ 39 % Zidovudine Cmin: 
AUC zidovudina: ↑ 39% Cmin zidovudina: 
The pharmacokinetics of indinavir (400 mg) with ritonavir (100 mg) dosed twice daily was examined in two studies.
Farmakokinetika indinavira (400 mg) primijenjenog s ritonavirom (100 mg) dvaput na dan ispitana je u dva ispitivanja.
Lamivudine AUC:  Lamivudine Cmin: 
AUC lamivudina:  Cmin lamivudina: 
Co-administration may result in decreased plasma concentrations of indinavir and as a consequence an increased risk for suboptimal treatment and facilitation of development of resistance (see section 4.5).
Istodobna primjena može dovesti do smanjene koncentracije indinavira u plazmi, čime se povećava rizik od suboptimalnog liječenja i olakšava razvoj rezistencije (vidjeti dio 4.5).
A boosted dose of 800 mg indinavir/100 mg ritonavir twice daily results in increased risk of adverse events.
Pojačana doza od 800 mg indinavira/100 mg ritonavira dvaput na dan dovodi do povećanog rizika od nuspojava.
3; and the mean increase in percent CD4 cell counts was 1.2 %.
3, a srednje povećanje udjela CD4 stanica iznosilo je 1,2%.
Talk to your doctor, pharmacist or nurse before taking CRIXIVAN if you have had or develop any of the following:
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete CRIXIVAN ako ste imali ili imate nešto od sljedećega:
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri su upala mrežnice uzrokovana citomegalovirusom, generalizirane i/ili fokalne infekcije mikobakterijama i pneumonija uzrokovana s Pneumocystis carinii.
Administration of indinavir with a meal high in calories, fat, and protein resulted in a blunted and reduced absorption with an approximate 80 % reduction in AUC and an 86 % reduction in Cmax.
Primjena indinavira uz visokokaloričan obrok bogat mastima i proteinima otežala je i smanjila apsorpciju te smanjila AUC za približno 80%, a Cmax za približno 86%.
Ritonavir may induce glucuronidation of methadone.
Ritonavir može inducirati glukuronidaciju metadona.
3; and the mean increase in percent CD4 cell counts was 4.2 %.
3, a srednje povećanje udjela CD4 stanica bilo je 4,2%.
In patients at increased risk, urinary screening should be considered.
U bolesnika u kojih postoji povećan rizik treba razmotriti provođenje pretraga mokraćnog sustava.
Complete cross resistance was noted between indinavir and ritonavir; however, cross resistance to saquinavir varied among isolates.
Između indinavira i ritonavira opažena je potpuna križna rezistencija, međutim, križna rezistencija na sakvinavir razlikovala se među izolatima.
Renal clearance (116 mL/min) of indinavir is concentration-independent over the clinical dose range.
Bubrežni klirens (116 ml/min) indinavira ne ovisi o koncentraciji kod doza iznad kliničkog raspona.
Based on an interaction study with lopinavir/ritonavir, combination of rosuvastatin and protease inhibitors is not recommended.
Na temelju rezultata ispitivanja interakcija s lopinavirom/ritonavirom, ne preporučuje se kombinacija rosuvastatina i inhibitora proteaze.